Company Overview

OmniAb, Inc. is a biotechnology platform company focused on antibody discovery technologies for pharmaceutical and biotechnology partners. The company licenses proprietary transgenic animal platforms and related discovery tools that enable partners to identify and develop therapeutic antibodies for a wide range of disease areas, including oncology, immunology, infectious diseases, neuroscience, and metabolic disorders. OmniAb operates within the broader biotechnology and life sciences tools industries, with revenue primarily derived from technology access agreements, research funding, milestone payments, and royalties tied to successful therapeutic commercialization.

The company originated from the antibody discovery business historically developed within Ligand Pharmaceuticals and became an independent publicly traded company in 2022 through a spin-off transaction. OmniAb’s strategic positioning is centered on offering a diversified suite of antibody discovery platforms designed to generate fully human or engineered antibodies with high specificity and therapeutic potential. Its technology portfolio includes transgenic rodents, chickens, and other discovery systems intended to broaden epitope coverage and improve antibody diversity relative to traditional approaches.

Business Operations

OmniAb generates revenue through collaborations with pharmaceutical and biotechnology companies that utilize its proprietary discovery platforms. Its principal operating capabilities include the OmniRat, OmniMouse, OmniChicken, and OmniClic platforms, along with associated screening and discovery technologies. These systems are designed to support therapeutic antibody generation across multiple modalities, including monoclonal antibodies, bispecific antibodies, and other engineered biologics. The company’s business model emphasizes long-term economics through downstream milestone and royalty participation tied to partner drug development programs.

The company operates primarily in the United States but maintains collaborative relationships with global biotechnology and pharmaceutical organizations across North America, Europe, and Asia-Pacific. OmniAb controls a portfolio of intellectual property related to transgenic animal technologies and antibody discovery methods. Its customer base includes emerging biotechnology firms as well as large multinational pharmaceutical companies. Public disclosures indicate the company maintains numerous active discovery partnerships, though specific economics and terms vary by agreement and are not always fully disclosed in public filings.

Strategic Position & Investments

OmniAb’s strategic direction focuses on expanding the adoption of its antibody discovery platforms while increasing the number of partnered therapeutic programs that may generate future milestone and royalty revenue. The company has emphasized broadening the diversity of its discovery technologies to address evolving biologic drug development trends, including multispecific antibodies and difficult-to-target antigens. Management has also highlighted the value of maintaining a capital-light platform model compared with traditional therapeutic drug developers.

The company continues to invest in platform innovation, artificial intelligence-enabled discovery workflows, and expansion of its partner network. OmniAb’s portfolio includes a large number of partnered therapeutic programs in preclinical and clinical development. Since becoming an independent company, OmniAb has focused on strengthening operational independence and expanding commercial partnerships rather than pursuing large-scale acquisitions. Public filings and investor materials identify ongoing investment in next-generation transgenic platforms and data-driven antibody optimization technologies.

Geographic Footprint

OmniAb is headquartered in Emeryville, California, and conducts operations primarily in the United States. Through licensing and research collaborations, the company maintains a global commercial presence spanning North America, Europe, and Asia-Pacific. Its technologies are used by pharmaceutical and biotechnology companies engaged in therapeutic development programs across multiple international markets.

The company’s operational influence is primarily driven through intellectual property licensing and collaborative research arrangements rather than extensive physical infrastructure outside the United States. Publicly disclosed partnerships indicate engagement with companies and research organizations in countries including the United States, China, Japan, and several European markets. Data regarding the precise geographic distribution of revenue is limited in publicly available disclosures.

Leadership & Governance

OmniAb’s leadership team is composed of biotechnology executives with backgrounds in biologics discovery, platform commercialization, and pharmaceutical partnerships. Management has consistently emphasized a strategy centered on scalable platform licensing, diversified partner exposure, and long-term royalty participation. The company operates under a governance structure typical of publicly traded biotechnology firms and files periodic disclosures with the SEC including annual reports and investor presentations.

Key executives include:

• Matt Foehr – Chief Executive Officer
• Kurt Gustafson – Chief Financial Officer
• Claire Del Vecchio – Chief Operating Officer
• John Higgins – General Counsel and Corporate Secretary
• Andrew Chung – Chief Scientific Officer

The company’s leadership has publicly communicated a strategic vision focused on expanding OmniAb’s role as a foundational antibody discovery partner to the global biopharmaceutical industry while increasing the long-term value of its partnered therapeutic pipeline.